Skip to main content
    L

    Legend Biotech Corp (LEGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.99
    -1.51 (-8.63%)

    Market Cap: $3.39B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Legend Biotech Corp (LEGN) P/E Ratio & Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Legend Biotech (LEGN) trades at 266.5x trailing earnings and 2.3x sales. Its P/S of 2.3x is below its 5-year median of 23.0x. Its forward P/E is 20.6x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 1193.7% higher over the next year.

    MultipleValue
    P/E (trailing)266.5x
    Forward P/E20.6x
    Price to sales2.3x
    Price to book2.4x
    PEGN/A
    FCF yield-10.4%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S2.3x23.0xN/A
    P/B2.4x8.0xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 6 year ends shown, its P/S ranged from 3.9x in 2025 to 72.7x in 2021. 2025 was the lowest of those years.

    Year endPriceP/SP/B
    2025$21.743.9x4.0x
    2024$32.549.5x5.7x
    2023$60.1737.5x8.7x
    2022$49.9272.0x10.7x
    2021$46.6172.7x8.9x
    2020$28.1646.1x6.2x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About LEGN

    What is LEGN's forward P/E ratio?

    Legend Biotech has a forward P/E ratio of 20.6x.

    Is LEGN stock overvalued?

    GNG's valuation label for LEGN is Undervalued.

    What is LEGN's price to sales ratio?

    Legend Biotech has a price to sales ratio of 2.3x.